Erbitux (cetuximab) - Eli Lilly, EMD Serono
motolimod (VTX 2337) - BMS
Celgene: Preliminary FY 2015 Results (Celgene) - Jan 15, 2016 - Anticipated data from P2 trial (NCT01836029) of motolimod + cetuximab for head and neck cancer in 2016 
Anticipated P2 data • Biosimilar • Head and Neck Cancer • Oncology
http://ir.celgene.com/releasedetail.cfm?ReleaseID=949787
 
Jan 15, 2016
 
.